يعرض 1 - 3 نتائج من 3 نتيجة بحث عن '"Gutierro Adúriz, I."', وقت الاستعلام: 0.96s تنقيح النتائج
  1. 1
    دورية أكاديمية
    Bioequivalence of a biosimilar enoxaparin sodium to Clexane® after single 100 mg subcutaneous dose: results of a randomized, double-blind, crossover study in healthy volunteers

    المؤلفون: Martínez González J, Monreal M, Ayani Almagia I, Llaudó Garín J, Ochoa Díaz de Monasterioguren L, Gutierro Adúriz I

    المصدر: Drug Design, Development and Therapy, Vol Volume 12, Pp 575-582 (2018)

    مصطلحات موضوعية: biosimilar, LMWH, pharmacodynamics, pharmacokinetics, anti-FXa, anti-FIIa, TFPI, Therapeutics. Pharmacology, RM1-950

    وصف الملف: electronic resource

    Relation: https://www.dovepress.com/bioequivalence-of-a-biosimilar-enoxaparin-sodium-to-clexanereg-after-s-peer-reviewed-article-DDDT; https://doaj.org/toc/1177-8881

    URL الوصول: https://doaj.org/article/729d1077ba1d482f95dbbd0c6223486f

    PDF full text from Publisher Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
  2. 2
    دورية أكاديمية
    Population pharmacokinetic modeling and simulations of long-acting intramuscular risperidone ISM®

    المؤلفون: Winkler, J., Snoeck, E., Llaudó Garin, J., Ayani, I., Martínez-González, J., Gutierro Adúriz, I.

    المصدر: In Clinical Therapeutics August 2015 37(8) Supplement:e3-e4

    View record from ScienceDirect Find this article in full text from ProQuest Full Text via ClinicalKey Full Text Finder
    أضف إلى المفضلة
  3. 3
    دورية أكاديمية
    Bioequivalence of a biosimilar enoxaparin sodium to Clexane ® after single 100 mg subcutaneous dose: results of a randomized, double-blind, crossover study in healthy volunteers.

    المؤلفون: Martínez González J; R&D Department, Laboratorios Farmacéuticos Rovi S.A., Madrid, Spain., Monreal M; R&D Department, Laboratorios Farmacéuticos Rovi S.A., Madrid, Spain., Ayani Almagia I; R&D Department, Laboratorios Farmacéuticos Rovi S.A., Madrid, Spain., Llaudó Garín J; R&D Department, Laboratorios Farmacéuticos Rovi S.A., Madrid, Spain., Ochoa Díaz de Monasterioguren L; R&D Department, Laboratorios Farmacéuticos Rovi S.A., Madrid, Spain., Gutierro Adúriz I; R&D Department, Laboratorios Farmacéuticos Rovi S.A., Madrid, Spain.

    المصدر: Drug design, development and therapy [Drug Des Devel Ther] 2018 Mar 19; Vol. 12, pp. 575-582. Date of Electronic Publication: 2018 Mar 19 (Print Publication: 2018).

    نوع المنشور: Equivalence Trial; Journal Article; Randomized Controlled Trial

    بيانات الدورية: Publisher: Dove Press Limited Country of Publication: New Zealand NLM ID: 101475745 Publication Model: eCollection Cited Medium: Internet ISSN: 1177-8881 (Electronic) Linking ISSN: 11778881 NLM ISO Abbreviation: Drug Des Devel Ther Subsets: MEDLINE

    مواضيع طبية MeSH: Therapeutic Equivalency*, Biosimilar Pharmaceuticals/*administration & dosage , Biosimilar Pharmaceuticals/*pharmacokinetics , Enoxaparin/*pharmacokinetics, Adolescent ; Adult ; Body Mass Index ; Cross-Over Studies ; Dose-Response Relationship, Drug ; Double-Blind Method ; Enoxaparin/administration & dosage ; Female ; Healthy Volunteers ; Humans ; Injections, Subcutaneous ; Male ; Young Adult

    PDF full text from Publisher Find this article in full text from ProQuest Full Text Finder
    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء